SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

BACKGROUND: International guidelines recommend severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for patients with cancer. A substantial risk of developing vaccine-related autoimmune toxicities could be hypothesised for patients with thymic epithelial tumours (TETs) due to their h...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Federica, Zucali, Paolo A., Galli, Giulia, Ballatore, Zelmira, Corti, Chiara, Aliaga, Pamela T., Uliano, Jacopo, Vivanet, Grazia, Curigliano, Giuseppe, Conforti, Fabio, Queirolo, Paola, Berardi, Rossana, Manglaviti, Sara, Apollonio, Giulia, Perrino, Matteo, Borea, Federica, D'Antonio, Federica, Garassino, Marina C., De Pas, Tommaso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872961/
https://www.ncbi.nlm.nih.gov/pubmed/35306318
http://dx.doi.org/10.1016/j.ejca.2022.02.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872961/
https://www.ncbi.nlm.nih.gov/pubmed/35306318
http://dx.doi.org/10.1016/j.ejca.2022.02.011

Ejemplares similares